Debiopharm joins Concr in the latest funding round

29 Nov 2023

We are thrilled to welcome Debiopharm as investors in the second tranche of our oversubscribed seed round.

Debiopharm Innovation Fund supports technologies that predict, enhance, and speed up the drug development process as well as those that improve the patient experience. Their thinking around biomarker-guided development and use of innovative technologies in drug development and cancer care resonated with Concr’s vision, and we are excited to leverage their expertise and network in growing Concr further.

Read this Sifted interview with Debiopharm’s Tom Gibbs and Cédric Odje, and Concr’s CBO Irina Babina to find out more about this partnership.